244 related articles for article (PubMed ID: 30655185)
21. Late-onset Pompe disease (LOPD) in Belgium: clinical characteristics and outcome measures.
Vanherpe P; Fieuws S; D'Hondt A; Bleyenheuft C; Demaerel P; De Bleecker J; Van den Bergh P; Baets J; Remiche G; Verhoeven K; Delstanche S; Toussaint M; Buyse B; Van Damme P; Depuydt CE; Claeys KG
Orphanet J Rare Dis; 2020 Apr; 15(1):83. PubMed ID: 32248831
[TBL] [Abstract][Full Text] [Related]
22. Targeted gene panel screening is an effective tool to identify undiagnosed late onset Pompe disease.
Savarese M; Torella A; Musumeci O; Angelini C; Astrea G; Bello L; Bruno C; Comi GP; Di Fruscio G; Piluso G; Di Iorio G; Ergoli M; Esposito G; Fanin M; Farina O; Fiorillo C; Garofalo A; Giugliano T; Magri F; Minetti C; Moggio M; Passamano L; Pegoraro E; Picillo E; Sampaolo S; Santorelli FM; Semplicini C; Udd B; Toscano A; Politano L; Nigro V
Neuromuscul Disord; 2018 Jul; 28(7):586-591. PubMed ID: 29880332
[TBL] [Abstract][Full Text] [Related]
23. New mutations and genotype-phenotype correlation in late-onset Pompe patients.
Bekircan-Kurt CE; Güneş HN; Yildiz FG; Saka E; Tan E; Erdem-Özdamar S
Acta Neurol Belg; 2017 Mar; 117(1):269-275. PubMed ID: 28032299
[TBL] [Abstract][Full Text] [Related]
24. Broad variation in phenotypes for common GAA genotypes in Pompe disease.
Niño MY; In't Groen SLM; de Faria DOS; Hoogeveen-Westerveld M; van den Hout HJMP; van der Ploeg AT; Bergsma AJ; Pijnappel WWMP
Hum Mutat; 2021 Nov; 42(11):1461-1472. PubMed ID: 34405923
[TBL] [Abstract][Full Text] [Related]
25. A Race Against Time-Changing the Natural History of CRIM Negative Infantile Pompe Disease.
Gupta P; Shayota BJ; Desai AK; Kiblawi F; Myridakis D; Messina J; Tah P; Tambini-King L; Kishnani PS
Front Immunol; 2020; 11():1929. PubMed ID: 33013846
[TBL] [Abstract][Full Text] [Related]
26. Pompe disease in a Brazilian series: clinical and molecular analyses with identification of nine new mutations.
Oba-Shinjo SM; da Silva R; Andrade FG; Palmer RE; Pomponio RJ; Ciociola KM; S Carvalho M; Gutierrez PS; Porta G; Marrone CD; Munoz V; Grzesiuk AK; Llerena JC; Berditchevsky CR; Sobreira C; Horovitz D; Hatem TP; Frota ER; Pecchini R; Kouyoumdjian JA; Werneck L; Amado VM; Camelo JS; Mattaliano RJ; Marie SK
J Neurol; 2009 Nov; 256(11):1881-90. PubMed ID: 19588081
[TBL] [Abstract][Full Text] [Related]
27. Homozygosity for the common GAA gene splice site mutation c.-32-13T>G in Pompe disease is associated with the classical adult phenotypical spectrum.
Musumeci O; Thieme A; Claeys KG; Wenninger S; Kley RA; Kuhn M; Lukacs Z; Deschauer M; Gaeta M; Toscano A; Gläser D; Schoser B
Neuromuscul Disord; 2015 Sep; 25(9):719-24. PubMed ID: 26231297
[TBL] [Abstract][Full Text] [Related]
28. A cross-sectional single-centre study on the spectrum of Pompe disease, German patients: molecular analysis of the GAA gene, manifestation and genotype-phenotype correlations.
Herzog A; Hartung R; Reuser AJ; Hermanns P; Runz H; Karabul N; Gökce S; Pohlenz J; Kampmann C; Lampe C; Beck M; Mengel E
Orphanet J Rare Dis; 2012 Jun; 7():35. PubMed ID: 22676651
[TBL] [Abstract][Full Text] [Related]
29. Pompe disease: early diagnosis and early treatment make a difference.
Chien YH; Hwu WL; Lee NC
Pediatr Neonatol; 2013 Aug; 54(4):219-27. PubMed ID: 23632029
[TBL] [Abstract][Full Text] [Related]
30. Respiratory function during enzyme replacement therapy in late-onset Pompe disease: longitudinal course, prognostic factors, and the impact of time from diagnosis to treatment start.
Stockton DW; Kishnani P; van der Ploeg A; Llerena J; Boentert M; Roberts M; Byrne BJ; Araujo R; Maruti SS; Thibault N; Verhulst K; Berger KI
J Neurol; 2020 Oct; 267(10):3038-3053. PubMed ID: 32524257
[TBL] [Abstract][Full Text] [Related]
31. Characteristics of Pompe disease in China: a report from the Pompe registry.
Zhao Y; Wang Z; Lu J; Gu X; Huang Y; Qiu Z; Wei Y; Yan C
Orphanet J Rare Dis; 2019 Apr; 14(1):78. PubMed ID: 30943998
[TBL] [Abstract][Full Text] [Related]
32. Description of clinical and genetic features of 122 patients included in the Spanish Pompe registry.
Martinez-Marin RJ; Reyes-Leiva D; Nascimento A; Muelas N; Dominguez-González C; Paradas C; Olivé M; García-Romero M; Pascual-Pascual SI; Grau JM; Barba-Romero MA; Gomez-Caravaca MT; de Las Heras J; Casquero P; Mendoza MD; de León JC; Gutierrez A; Morís G; Blanco-Lago R; Ramos-Fransi A; Pintós G; García-Antelo MJ; Rabasa M; Morgado Y; Usón M; Miralles FJ; Bárcena-Llona JE; Gómez-Belda AB; Pedraza-Hueso MI; Hortelano M; Colomé A; Garcia-Martin G; Lopez de Munain A; Jericó I; Galán-Dávila L; Pardo J; Salgueiro-Origlia G; Alonso-Pérez J; Pla-Junca F; Schiava M; Segovia-Simón S; Díaz-Manera J
Neuromuscul Disord; 2024 Jan; 34():1-8. PubMed ID: 38087756
[TBL] [Abstract][Full Text] [Related]
33. A Comprehensive Update on Late-Onset Pompe Disease.
Labella B; Cotti Piccinelli S; Risi B; Caria F; Damioli S; Bertella E; Poli L; Padovani A; Filosto M
Biomolecules; 2023 Aug; 13(9):. PubMed ID: 37759679
[TBL] [Abstract][Full Text] [Related]
34. The emerging phenotype of late-onset Pompe disease: A systematic literature review.
Chan J; Desai AK; Kazi ZB; Corey K; Austin S; Hobson-Webb LD; Case LE; Jones HN; Kishnani PS
Mol Genet Metab; 2017 Mar; 120(3):163-172. PubMed ID: 28185884
[TBL] [Abstract][Full Text] [Related]
35. Screening for late-onset Pompe disease in Internal Medicine departments in Spain.
López-Rodríguez M; Torralba-Cabeza MA; de Pedro IP; Rivera A; Gil RS; Gómez-Belda A; de la Peña JLP; de Los Santos Moreno A; Selva-O'Callaghan A; Gárate IG; García AG; Hurtado R; de Ureta PT; Barba-Romero MÁ; Milisenda JC; Grau-Junyent JM;
Orphanet J Rare Dis; 2023 Aug; 18(1):256. PubMed ID: 37653444
[TBL] [Abstract][Full Text] [Related]
36. Infantile Pompe disease on ERT: update on clinical presentation, musculoskeletal management, and exercise considerations.
Case LE; Beckemeyer AA; Kishnani PS
Am J Med Genet C Semin Med Genet; 2012 Feb; 160C(1):69-79. PubMed ID: 22252989
[TBL] [Abstract][Full Text] [Related]
37. White matter lesions in treated late onset Pompe disease are not different to matched controls.
Schneider I; Hensel O; Zierz S
Mol Genet Metab; 2019 Jun; 127(2):128-131. PubMed ID: 31153821
[TBL] [Abstract][Full Text] [Related]
38. Late-Onset Pompe Disease with Normal Creatine Kinase Levels: The Importance of Rheumatological Suspicion.
Marotto D; Moschetti M; Lo Curto A; Spezzigu AM; Giacomarra M; Marsana EM; Zizzo C; Duro G; Colomba P
Int J Mol Sci; 2023 Nov; 24(21):. PubMed ID: 37958907
[TBL] [Abstract][Full Text] [Related]
39. Effects of short-to-long term enzyme replacement therapy (ERT) on skeletal muscle tissue in late onset Pompe disease (LOPD).
Ripolone M; Violano R; Ronchi D; Mondello S; Nascimbeni A; Colombo I; Fagiolari G; Bordoni A; Fortunato F; Lucchini V; Saredi S; Filosto M; Musumeci O; Tonin P; Mongini T; Previtali S; Morandi L; Angelini C; Mora M; Sandri M; Sciacco M; Toscano A; Comi GP; Moggio M
Neuropathol Appl Neurobiol; 2018 Aug; 44(5):449-462. PubMed ID: 28574618
[TBL] [Abstract][Full Text] [Related]
40. Skeletal alterations, developmental delay and new mutations in juvenile-onset Pompe disease.
Guevara-Campos J; González-Guevara L; Cauli O
Neuromuscul Disord; 2019 Mar; 29(3):192-197. PubMed ID: 30595407
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
